keyword
MENU ▼
Read by QxMD icon Read
search

Her2 positive, hormone positive

keyword
https://www.readbyqxmd.com/read/28108967/specific-sites-of-metastases-in-invasive-lobular-carcinoma-a-retrospective-cohort-study-of-metastatic-breast-cancer
#1
Masayuki Inoue, Hiroshi Nakagomi, Haruka Nakada, Kazushige Furuya, Kou Ikegame, Hideki Watanabe, Masao Omata, Toshio Oyama
BACKGROUND: Invasive lobular carcinoma (ILC) is known to be the second most common histological type following invasive ductal carcinoma (IDC). Definitive clinical features of ILC are controversial. METHODS: We retrospectively analyzed a cohort of 330 patients with metastatic breast cancer, 303 of IDC, 19 of ILC, and 8 of others. We compared the patient age and tumor-node-metastasis factors, disease-free survival (DFS), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression at the primary site between ILC and IDC...
January 20, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28102883/exploring-prognostic-factors-for-her2-positive-metastatic-breast-cancer-a-retrospective-cohort-study-in-a-major-swiss-hospital
#2
Lilian Bringolf, Bernhard Pestalozzi, Daniel Fink, Konstantin Dedes
BACKGROUND: Trastuzumab (Herceptin®, Roche) has significantly improved the prognosis of patients with HER2-positive metastatic breast cancer. Some patients remain in remission for many years. However, there are no prognostic markers associated with long-term survival. This study aimed to analyse treatment patterns of HER2-positive metastatic breast cancer at a single institution and explore prognostic factors for long-term survival after HER2-targeted treatment. PATIENTS AND METHODS: This was a retrospective cohort study of all patients with HER2-positive metastatic breast cancer receiving first-line treatment with HER2-targeted therapy between 2004 and 2014 at the University Hospital of Zurich (n = 81)...
January 19, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/28101678/breast-carcinoma-subtypes-show-different-patterns-of-metastatic-behavior
#3
István Artúr Molnár, Béla Ákos Molnár, Laura Vízkeleti, Krisztina Fekete, Judit Tamás, Péter Deák, Csilla Szundi, Borbála Székely, Judit Moldvay, Stefan Vári-Kakas, Marcell A Szász, Balázs Ács, Janina Kulka, Anna-Mária Tőkés
The aim of our retrospective study was to analyze patterns of subtype specific metastatic spread and to identify the time course of distant metastases. A consecutive series of 490 patients with breast cancer who underwent surgery and postoperative treatment at Semmelweis University, Hungary, and diagnosed between the years 2000 and 2007 was identified from the archives of the 2nd Department of Pathology, Hungary. Molecular subtypes were defined based on the 2011 St. Gallen recommendations. Statistical analysis was performed with SPSS Statistics for Windows, Version 22...
January 19, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28099174/discordance-rate-in-estrogen-receptor-progesterone-receptor-her2-status-and-ki67-index-between-primary-unifocal-and-multiple-homogenous-breast-carcinomas-and-synchronous-axillary-lymph-node-metastases-have-an-impact-on-therapeutic-decision
#4
Rares Georgescu, Monica Boros, Denisa Moncea, Orsolya Bauer, Marius-Florin Coros, Adela Oprea, Cosmin Moldovan, Cristian Podoleanu, Simona Stolnicu
BACKGROUND: We aimed to demonstrate that in breast carcinomas the tumor profile is not stable during the metastatic process, with impact on therapeutic decisions. MATERIALS AND METHODS: We analyzed the estrogen receptor (ER), progesterone receptor (PR), and HER2 status and Ki67 index in 41 primary unifocal (PU) and 37 primary multiple (PM) breast carcinomas with identical immunohistochemical profiles among multiple tumor foci and the matched axillary lymph node metastases...
January 17, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28071616/presenting-features-treatment-patterns-and-outcomes-of-patients-with-breast-cancer-in-pakistan-experience-at-a-university-hospital
#5
S Kumar, A J Shaikh, Y A Rashid, N Masood, Atv Mohammed, U Z Malik, G Haider, N Niamutullah, S Khan
BACKGROUND: Breast cancer is the most common cancer in Pakistani women. We report the presenting features, treatment patterns and survival of breast cancer from a University Hospital in Southern Pakistan and compare the data with international population based studies. MATERIALS AND METHODS: Medical records of patients diagnosed to have breast cancer between January 1999 and November 2008 were reviewed retrospectively. RESULTS: A total of 845 patients were identified...
April 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28068979/first-report-on-molecular-breast-cancer-subtypes-and-their-clinico-pathological-characteristics-in-eastern-morocco-series-of-2260-cases
#6
Manal Elidrissi Errahhali, Mounia Elidrissi Errahhali, Meryem Ouarzane, Tijani El Harroudi, Said Afqir, Mohammed Bellaoui
BACKGROUND: Breast cancer is the most frequent malignancy among women in Eastern Morocco. In this paper, we provide the first report on molecular breast cancer subtypes in this region. This is the largest population-based study on breast cancer among Moroccan women. METHODS: We analyzed 2260 breast cancer cases diagnosed at the Hassan II Regional Oncology Center between October 2005 and December 2012. Clinico-pathological and therapeutic features were studied. Molecular subtypes were determined and their associations with the clinico-pathological characteristics of the tumors were examined...
January 9, 2017: BMC Women's Health
https://www.readbyqxmd.com/read/28058615/complete-remission-in-metastatic-breast-cancer-expecting-the-unexpected-results-of-a-cross-sectional-study
#7
Giulia Galli, Anna Tessari, Luca Porcu, Giacomo Bregni, Biagio Paolini, Maria Luisa Carcangiu, Massimiliano Gennaro, Maria Carmen De Santis, Laura Lozza, Filippo de Braud, Serena Di Cosimo
BACKGROUND: Complete response (CR) in metastatic breast cancer (MBC) is rare. This study aims at analyzing the characteristics and outcome of MBC patients achieving CR. METHODS: We performed a cross-sectional analysis of clinical data from a consecutive series of MBC patients admitted at the Division of Medical Oncology of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, achieving CR following treatment for systemic disease and with at least 2 years of follow-up...
January 5, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28057355/physical-activity-and-breast-cancer-risk-by-pathological-subtype
#8
Virginia Lope, Miguel Martín, Adela Castelló, Soraya Casla, Amparo Ruiz, Jose Manuel Baena-Cañada, Ana Mª Casas, Lourdes Calvo, Begoña Bermejo, Montserrat Muñoz, Manuel Ramos, Ana de Juan-Ferré, Carlos Jara, Antonio Antón, Mª Ángeles Jimeno, Ana Lluch, Silvia Antolín, José Ángel García-Sáenz, Purificación Estévez, Esperanza Arriola-Arellano, Joaquín Gavilá, Beatriz Pérez-Gómez, Eva Carrasco, Marina Pollán
OBJECTIVE: To examine the influence of physical activity on breast cancer risk and evaluate whether adherence to international recommendations is associated with a decreased risk. METHODS: This is a multicenter matched case-control study where 698 pairs completed a physical activity questionnaire. Recreational physical activity during the last year was quantified in metabolic equivalent hours per week (MET-h/week) and categorized in activities of moderate (3.0-5...
January 2, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28051275/ratio-of-proliferation-markers-and-hsp90-gene-expression-as-a-predictor-of-pathological-complete-response-in-breast-cancer-neoadjuvant-chemotherapy
#9
Michal Jarzab, Monika Kowal, Wieslaw Bal, Malgorzata Oczko-Wojciechowska, Justyna Rembak-Szynkiewicz, Malgorzata Kowalska, Ewa Stobiecka, Ewa Chmielik, Tomasz Tyszkiewicz, Malgorzata Kaszuba, Elzbieta Nowicka, Barbara Lange, Agnieszka Czarniecka, Jolanta Krajewska, Alicja Dyla, Miroslaw Dobrut, Dariusz Lange, Barbara Jarzab, Barbara Bobek-Billewicz, Rafal Tarnawski
INTRODUCTION: Prediction of response to preoperative breast cancer chemotherapy may offer a substantial optimization of medical management of this disease. The most efficient prediction would be done a priori, before the start of chemotherapy and based on the biological features of patient and tumor. Numerous markers have been proposed but none of them has been applied as a routine. The role of MKI67 and HSP90 expression has been recently suggested to predict treatment sensitivity in HER2-positive breast cancer...
2016: Folia Histochemica et Cytobiologica
https://www.readbyqxmd.com/read/28042209/comparison-of-immunocytochemistry-and-immunohistochemistry-on-breast-carcinoma-a-boon-or-a-bane
#10
Kempula Geethamala, Venkataramappa Srinivasa Murthy, Bangalore Ramalingiah Vani, Madireddi Sudha Rao, Malugnalli Uddappa Thejaswini, Krishnarajapet Padmanabha Padmaja
INTRODUCTION: Breast carcinoma is the most common cancer among women in the urban Indian population. Conventionally, immunohistochemistry (IHC) is done to determine the hormone receptor status of the tumor. Immunocytochemistry (ICC) on fine-needle aspiration cytology (FNAC) was carried out to determine the same hormone receptor status of the tumor. OBJECTIVE: The study was undertaken to evaluate the diagnostic reliability of performing estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2/neu) receptor status on FNAC by ICC and to compare the results with IHC...
January 2017: Journal of Laboratory Physicians
https://www.readbyqxmd.com/read/28041972/breast-cancer-biomarkers-before-and-after-neoadjuvant-chemotherapy-does-repeat-testing-impact-therapeutic-management
#11
Zhaoying Xian, Alexander K Quinones, Gary Tozbikian, Debra L Zynger
In patients treated with neoadjuvant chemotherapy (NAC), there is no consensus on retesting biomarkers within the excision specimen. Our aim was to investigate the clinical relevance of biomarker changes post-NAC at a large tertiary medical center. A retrospective search was performed to identify cases from 2012-2015 with needle biopsy confirmed invasive breast carcinoma treated with NAC and subsequent excision containing residual invasive tumor. Biomarkers (estrogen receptor (ER), progesterone receptor (PR), and HER2/neu (HER2)) were performed on all pre-NAC biopsies...
December 29, 2016: Human Pathology
https://www.readbyqxmd.com/read/28040858/multicenter-analysis-of-neoadjuvant-docetaxel-carboplatin-and-trastuzumab-in-her2-positive-breast-cancer
#12
Isabel Echavarria, Mónica Granja, Coralia Bueno, Sara Lopez-Tarruella, Paloma Peinado, Miguel Sotelo, Yolanda Jerez, Fernando Moreno, Gabriela Torres, Miriam Lobo, Ivan Marquez-Rodas, Maria Del Monte-Millan, Miguel Martín, Jose Angel García-Saenz
PURPOSE: In an era where neoadjuvant dual blockade is emerging as the standard of care for early and locally advanced HER2-positive breast cancer, we aimed to identify predictors of response to single-blockade chemotherapy. METHODS: This retrospective analysis reviewed all the incident stage I-III HER2-positive breast cancer patients who received neoadjuvant docetaxel, carboplatin, and trastuzumab (TCH) in three institutions. pCR was defined as the absence of invasive tumor in breast and axillary nodes (ypT0/isypN0)...
December 31, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28038704/gata3-expression-in-clinically-useful-groups-of-breast-carcinoma-a-comparison-with-gcdfp15-and-mammaglobin-for-identifying-paired-primary-and-metastatic-tumors
#13
Yuqiong Yang, Shanming Lu, Wenqin Zeng, Shoucheng Xie, Shengjun Xiao
GATA3 has been recognized as the novel marker for identifying primary and metastatic breast carcinomas, consistently showing that GATA3 was significantly more sensitive than traditional markers gross cystic disease fluid protein 15 (GCDFP15) and mammaglobin (MGB). However, clinically useful groups of breast carcinomas status were not identified, which were determining appropriate treatment strategy, affecting the prognosis. In this study, we undertook a comparative study of the marker GATA3 and GCDFP15 and MGB in clinically useful groups of paired primary and metastatic breast cancer...
February 2017: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/28029660/phenotypic-characterization-of-circulating-tumor-cells-in-triple-negative-breast-cancer-patients
#14
Sofia Agelaki, Melina Dragolia, Harris Markonanolaki, Saad Alkahtani, Christos Stournaras, Vassilis Georgoulias, Galatea Kallergi
INTRODUCTION: Patients with triple negative breast cancer (TNBC), are considered as a poor prognosis group for whom no targeted therapies are currently available. The aim of the present study was to phenotypically characterize their CTCs in order to explore potential therapeutic targets. METHODS: PBMC's cytospins were prepared from 45 early (before and after adjuvant chemotherapy), 10 metastatic TNBC and 21 hormone receptor (HR) -positive patients. The expression of Cytokeratins (CK), ER, PR, EGFR and HER2 on CTCs was assessed using immunofluoresence staining and ARIOL analysis...
December 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/28028261/-two-cases-of-er-positive-postmenopausal-breast-cancer-that-increased-in-size-during-neoadjuvant-hormone-therapy
#15
Takanori Jinno, Yasuhiro Kurumiya, Tae Niwa, Ei Sekoguchi, Satoshi Kobayashi, Kiyotaka Kawai, Muneyasu Kiriyama
The first patient was a 62-year-old woman who was referred to our hospital with the complaint of a left breast tumor. She was diagnosed with invasive ductal carcinoma(T1N0M0, stage I). The tumor was ER-positive, PgR-negative, and HER2- negative. She was treated with toremifene, letrozole, and anastrozole as neoadjuvant hormone therapy for 4 months, but the tumor increased in size. The clinical response was judged as progressive disease, and a left partial mastectomy and axillary lymph node dissection were performed...
December 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28027327/mutational-profile-of-metastatic-breast-cancers-a-retrospective-analysis
#16
Celine Lefebvre, Thomas Bachelot, Thomas Filleron, Marion Pedrero, Mario Campone, Jean-Charles Soria, Christophe Massard, Christelle Lévy, Monica Arnedos, Magali Lacroix-Triki, Julie Garrabey, Yannick Boursin, Marc Deloger, Yu Fu, Frédéric Commo, Véronique Scott, Ludovic Lacroix, Maria Vittoria Dieci, Maud Kamal, Véronique Diéras, Anthony Gonçalves, Jean-Marc Ferrerro, Gilles Romieu, Laurence Vanlemmens, Marie-Ange Mouret Reynier, Jean-Christophe Théry, Fanny Le Du, Séverine Guiu, Florence Dalenc, Gilles Clapisson, Hervé Bonnefoi, Marta Jimenez, Christophe Le Tourneau, Fabrice André
BACKGROUND: Major advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet limited information is available on the genomic profile of this disease. This study aims to decipher mutational profiles of mBC using next-generation sequencing. METHODS AND FINDINGS: Whole-exome sequencing was performed on 216 tumor-blood pairs from mBC patients who underwent a biopsy in the context of the SAFIR01, SAFIR02, SHIVA, or Molecular Screening for Cancer Treatment Optimization (MOSCATO) prospective trials...
December 2016: PLoS Medicine
https://www.readbyqxmd.com/read/28008158/similar-outcomes-between-adenoid-cystic-carcinoma-of-the-breast-and-invasive-ductal-carcinoma-a-population-based-study-from-the-seer-18-database
#17
Qing-Xia Chen, Jun-Jing Li, Xiao-Xiao Wang, Pei-Yang Lin, Jie Zhang, Chuan-Gui Song, Zhi-Ming Shao
Adenoid cystic carcinoma of the breast (breast-ACC) is a rare and indolent tumor with a good prognosis despite its triple-negative status. However, we observed different outcomes in the present study. Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, we enrolled a total of 89,937 eligible patients with an estimated 86 breast-ACC cases and 89,851 invasive ductal carcinoma (IDC) patients. In our study, breast-ACC among women presented with a higher proportion of triple-negative breast cancer (TNBC), which was more likely to feature well-differentiated tumors, rare regional lymph node involvement and greater application of breast-conserving surgery (BCS)...
December 20, 2016: Oncotarget
https://www.readbyqxmd.com/read/28007942/everolimus-boosts-endocrine-therapy-for-breast-cancer
#18
(no author information available yet)
In a phase II trial, the mTOR inhibitor everolimus, combined with the endocrine therapy fulvestrant, improved progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer who had become resistant to aromatase inhibitors.
December 22, 2016: Cancer Discovery
https://www.readbyqxmd.com/read/28005906/a-stromal-immune-module-correlated-with-the-response-to-neoadjuvant-chemotherapy-prognosis-and-lymphocyte-infiltration-in-her2-positive-breast-carcinoma-is-inversely-correlated-with-hormonal-pathways
#19
Anne-Sophie Hamy, Hélène Bonsang-Kitzis, Marick Lae, Matahi Moarii, Benjamin Sadacca, Alice Pinheiro, Marion Galliot, Judith Abecassis, Cecile Laurent, Fabien Reyal
INTRODUCTION: HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive tumors are required to improve the prediction of prognosis and to develop novel therapeutic interventions. METHODS: We analyzed 2893 primary human breast cancer samples from 21 publicly available datasets and developed a six-metagene signature on a training set of 448 HER2-positive BC...
2016: PloS One
https://www.readbyqxmd.com/read/28002848/multidisciplinary-approach-to-neoadjuvant-endocrine-therapy-in-breast-cancer-a-comprehensive-review
#20
Tomás Reinert, Susana Ramalho, Rodrigo Gonçalves, Carlos Henrique Barrios, Marcia Silveira Graudenz, José Bines
Breast cancer is the most common type of cancer and the leading cause of cancer-related death among women worldwide. Hormone receptor-positive (HR+) tumors represent the most common form of this disease, with more than 70% of breast cancers expressing these receptors. Response and benefit to neoadjuvant chemotherapy (NCT) varies according to HR expression, with lower responses in luminal tumors as compared with hormone receptor-negative (HR-) and human epidermal growth factor receptor 2-positive (HER2+) tumors...
December 21, 2016: Revista Brasileira de Ginecologia e Obstetrícia
keyword
keyword
21972
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"